China Approves World's First Invasive Brain-Computer Chip for Clinical Use, Marking Global Milestone

China has achieved a monumental medical breakthrough with the approval of NEO, the world's first invasive brain-computer interface (BCI) product for use beyond clinical trials. This landmark decision offers unprecedented hope to individuals suffering from paralysis, exemplified by the remarkable recovery of Dong Hui. Six years after a devastating car accident left him paralyzed from the neck down, Dong, 39, was able to write his name and express gratitude, an achievement made possible by an 11-month rehabilitation journey powered by the brain implant. His initial inability to use his fingers transformed into the ability to perform complex motor tasks, marking a significant personal victory and a global medical milestone. The coin-sized NEO device, developed by Shanghai-based Neuracle Technology in collaboration with Tsinghua University, is at the heart of this innovation. During a swift 90-minute procedure, NEO's eight sensors are placed on the dura mater, the protective outer layer of the brain, to collect neural signals. These signals are then transmitted to a skull-mounted implant and subsequently to a computer, which translates them into commands for a soft robotic glove worn by the patient. Dong's rehabilitation began just a week post-surgery, leading to a "miraculous moment" on the ninth day when he successfully grabbed a ball without the glove. He now continues his training at home, aiming for greater independence in daily tasks. NEO's swift approval, outpacing competitors like Elon Musk's Neuralink, is attributed to its "relatively less invasive" design. Unlike Neuralink's N1 chip, which directly penetrates the brain's cortex, NEO's sensors rest on the dura mater. This design significantly reduces risks such as hemorrhage, glial scarring, and long-term signal degradation, thereby facing fewer regulatory hurdles. China's National Medical Products Administration has approved NEO for patients aged 18 to 60 with limb paralysis due to spinal cord injuries who retain some residual arm function, paving the way for thousands to follow Dong's path. The rapid regulatory pathway for NEO underscores China's robust support for its burgeoning BCI industry. While the US FDA approval process can span several years, China's government has actively expedited such innovations. The country's latest five-year plan explicitly lists BCI as one of six critical industries for future technological competitiveness, alongside quantum technology and humanoid robots. This strategic backing extends to financial support and the swift integration of NEO into the national health insurance system, assigning it a unique code to facilitate patient access and affordability. This global milestone signifies that BCIs are transitioning from laboratory research to large-scale manufacturing and widespread clinical application, as noted by neuroscientist Wang Shouyan. For Dong Hui, the impact is profoundly personal: "Now, it will be able to help not only me, but also thousands and thousands of other patients suffering from spinal cord injuries in China who are tortured by despair each day. It will bring them hope and change their lives." China's commitment to becoming a global leader in this field, driven by both government policy and a receptive public, positions it at the forefront of a medical revolution that promises to redefine human capabilities and quality of life.